Understanding HER2-Low mBC

 

ESMO 2022 Conference Coverage
N

ESMO 2022 on DESTINY-Breast04 Patient-Reported Outcomes: T-DXd vs. TPC in HER2-Low mBC

By ESMO 2022 Conference Coverage FEATURING Naoto Ueno
By ESMO 2022 Conference Coverage FEATURING Naoto Ueno
470 views
October 3, 2022
0 Comments
Login to view comments. Click here to Login
Understanding HER2-low mBC
14:22
Winship Cancer Institute - Emory University

Defining and Identifying HER2-Low Breast Cancer

Feat. J. Meisel
10:21
ecancer

Novel ADCs for Management of mBC

Feat. H. Rugo
07:13
ecancer

Overview of the Management of HER2-Low Breast Cancer Patients

Feat. H. Rugo
06:46
ecancer

2023 Updates on HER2-Low Breast Cancer

Feat. S. Al Sukhun
29:53
Keck School of Medicine of USC

Advances in Treatment of HER2+ BC in 2023

Feat. W. Gradishar
13:32
Dana-Farber Cancer Institute

Impact of DESTINY-Breast04 Data in HER2-Low Breast Cancer: How to Im…

Feat. P. Tarantino
03:14
SABCS 2022 Conference Coverage

SABCS 2022: Comprehensive Genomic Characterization of HER2-Low Breas…

Feat. P. Tarantino
06:51
SABCS 2022 Conference Coverage

SABCS 2022: Genomic and Transcriptomic Landscape of HER2-Low Breast …

Feat. R. Bansal
09:42
ESMO 2022 Conference Coverage

ESMO 2022 on DESTINY-Breast04 Patient-Reported Outcomes: T-DXd vs. T…

Feat. N. Ueno
15:50
Susan Dent

Management of HR+/HER2- Advanced BC: Future Directions

05:51
Penn Medicine Abramson Cancer Center

The New Paradigm of HER2-Low Breast Cancer

Feat. M. Mahler